Tata Consultancy Services (TCS)

Similar documents
Tata Consultancy Services (TCS)

Tata Consultancy Services (TCS)

Wipro ACCUMULATE. Performance Highlights CMP. `539 Target Price `582. 1QFY2017 Result Update IT. Investment Period 12 Months

Tech Mahindra ACCUMLATE. Performance Highlights `495 `526. CMP Target Price. 2QFY2018 Result Update IT

Amber Enterprises India Ltd

Parag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months

Wipro BUY. Performance Highlights. CMP Target Price `539 `680. 4QFY2016 Result Update IT. 3-year price chart. Key financials (Consolidated, IFRS)

Parag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months

Mahindra & Mahindra Ltd.

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Rallis India NEUTRAL. Performance Highlights CMP. `237 Target Price - 1QFY2018 Result Update Agrichemical. Investment Period - 3-year price chart

Hindustan Media Ventures

TV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months

Inox Wind BUY. Performance Highlights. CMP Target Price `390 `505. 2QFY2016 Result Update Capital Goods. 3 year price chart

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

Rallis India NEUTRAL. Performance Highlights CMP. `215 Target Price - 3QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Rallis India NEUTRAL. Performance Highlights CMP. `242 Target Price - 4QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Coal India ACCUMULATE. Performance Highlights CMP. `338 Target Price `380. Outlook and valuation. 2QFY2016 Result Update Mining

Mahindra & Mahindra Ltd.

Maruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart

Tata Steel NEUTRAL. Performance Highlights CMP. `226 Target Price - 2QFY2016 Result Update Steel. Investment Period - 3-year price chart

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Tech Mahindra ACCUMULATE. Performance Highlights. CMP Target Price `659 `693. 3QFY2012 Result Update IT. Key financials (Consolidated, Indian GAAP)

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Rallis India SELL. Performance Highlights. `231 Target Price 189 CMP. 2QFY2018 Result Update Agrichemical. Investment Period 12 months

Music Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Bata India BUY. Performance Update. CMP `1,008 Target Price `1,243. 2QFY2019 Result Update Footwear. Historical share price chart.

Music Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.

Maruti Suzuki India BUY. Performance Update. CMP `6,705 Target Price `8,552. 2QFY2019 Result Update Automobile. Historical share price chart

Procter & Gamble Hygiene & Health Care

Tech Mahindra ACCUMULATE. Performance Highlights CMP. `955 Target Price `1,070. 2QFY2013 Result Update IT. Investment Period 12 months

Asian Granito BUY. Performance Highlights CMP. `270 Target Price `351. Outlook and valuation. 3QFY2017 Result Update Ceramics

ACC BUY. Performance Highlights. CMP `1,397 Target Price `1,630. 3QCY2015 Result Update Cement

Sanofi India NEUTRAL. Performance Highlights. CMP `4,301 Target Price - 4QCY2016 Result Update Pharmaceutical. Investment Period - 3-year price chart

Goodyear India BUY. Company Update. CMP Target Price `515 `631. Company Update Tyres. 3-year Daily Price Chart. Key Financials

Amara Raja Batteries BUY. Performance Highlights. CMP `1,010 Target Price `1,167. 2QFY2017 Result Update Auto Ancillary. 3-year price chart

Hero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,226 Target Price `3,466. 3QFY2017 Result Update Automobile. 3-year price chart

Jindal Steel & Power BUY. CMP Target Price `200 `320. 1QFY2019 Result Update Steel & Power. Performance Update

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart.

TV Today Network BUY. Performance Update. CMP Target Price `315 `385. 2QFY2017 Result Update Media. Historical share price chart.

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `495 Target Price - 4QFY2017 Result Update Pharmaceutical.

Reliance Communication

Ambuja Cements ACCUMULATE. Performance Highlights. CMP Target Price `207 `233. 3QCY2015 Result Update Cement. Quarterly results (Standalone)

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months

Dr. Reddy s Laboratories

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

HDFC Bank BUY. Performance Highlights. CMP `1,965 Target Price `2,350. Q2FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

LIC Housing Finance BUY. Performance Highlights. CMP Target Price `532 `630. 3QFY2017 Result Update HFC. 3-Year Daily Price Chart

HDFC Bank BUY. Operating performance strong; improved NIM. CMP `2,268 Target Price `2,500. Q4FY2019 Result Update Banking. 3-year price chart

HDFC Bank BUY. Performance Highlights. CMP `2,145 Target Price `2,500. Q3FY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

Greenply Industries BUY. The plywood maker for growing India. Target Price. Initiating Coverage Plywood. 3-year price chart.

KPIT Cummins ACCUMULATE. Performance Highlights CMP. `121 Target Price `132. 2QFY2013 Result Update IT. Investment Period 12 Months

Federal Bank BUY. Performance Highlights. Target Price. 1QFY2018 Result Update Banking. Stock Info Sector

Aurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months

ICICI Bank BUY. Performance Highlights. CMP Target Price `343 `460. Q3FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

Lupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart

CCL Products BUY. Brewing Steadily. CMP Target Price `300 `360. Initiating Coverage Coffee. January 4, year price chart

Sanofi India ACCUMULATE. Performance Highlights. CMP `4,410 Target Price `4,738. 1QCY2016 Result Update Pharmaceutical. 3-year price chart

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `440 Target Price. 3QFY2017 Result Update Pharmaceutical. Investment Period -

ICICI Bank BUY. Performance Highlights. CMP Target Price `328 `416. 3QFY2018 Result Update Banking. 3-year price chart. Key financials (Standalone)

Axis Bank BUY. CMP Target Price `620 `750. Update Bank. Earnings to normalize with stabilizing credit costs. 3-year price chart.

Lupin 1QFY2018 Result Update

Dr Reddy s Laboratories

LT Foods BUY. Performance Update. CMP Target Price `92 `128. 3QFY2018 Result Update Media February 12, 2018

KEI Industries BUY. Performance Update. CMP Target Price `433 `508. 4QFY2018 Result Update Cable. Historical share price chart.

KEI Industries BUY. Performance Update. Target Price. 3QFY2018 Result Update Cable. Historical share price chart. Key Financials

GAIL India NEUTRAL. Performance Highlights CMP. `363 Target Price - 2QFY2013 Result Update Oil & Gas. Investment Period -

Quick take. VIP Industries BUY. Travelling smart on the luggage track. CMP Target Price `153 ` year daily price chart

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `390 Target Price - 2QFY2017 Result Update Pharmaceutical. Investment Period -

SpiceJet BUY. Performance Highlights CMP. `32 Target Price `43. 1QFY2013 Result Update Airlines. Investment Period 12 Months.

Goodyear India ACCUMULATE. Performance Highlights. CMP Target Price `326 `374. 1QCY2012 Result Update Tyres. Key financials

ICICI Bank BUY. Performance Highlights. CMP Target Price `307 `411. 1QFY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

LT Foods BUY. Performance Update. CMP Target Price `76 `128. 4QFY2018 Result Update Media

Transport Corporation of India

Matrimony.com Ltd BUY. A complete package from matchmaking to wedding. Target Price. Initiating Coverage Internet Software & Services

Cipla REDUCE. Performance Highlights. CMP Target Price `564 `490. 2QFY2017 Result Update Pharmaceutical. Investment Period - 3-Year Daily Price Chart

MRF BUY. Performance Highlights. CMP `9,407 Target Price `11,343. Company Update Automobile. Key financials

Graphite India BUY. Performance Highlights. CMP Target Price `88 `109. 1QFY2012 Result Update Capital Goods

CCL Products BUY. Performance Update. CMP Target Price `278 `360. 3QFY2018 Result Update Coffee. Historical share price chart.

Graphite India BUY. Performance Highlights CMP. `93 Target Price `124. 4QFY2012 Result Update Capital Goods. Investment Period 12 Months

Aurobindo Pharma BUY. Performance Highlights CMP. `580 Target Price `823. 4QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Mahindra & Mahindra Ltd.

Hero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,718 Target Price `4,130. 1QFY2018 Result Update Automobile. 3-year price chart

Sun Pharma BUY. Performance Highlights. `783 Target Price `944 CMP. 1QFY2017 Result Update Pharmaceutical. Investment Period 12 months

FY2017 FY2018E FY2019E

KPIT Cummins BUY. Performance Highlights CMP. `105 Target Price `135. 4QFY2013 Result Update IT. Investment Period 12 Months

Sun Pharma BUY. Performance Highlights. `683 Target Price `847 CMP. 2QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Dr. Reddy s Laboratories

ACC NEUTRAL. Performance Highlights. CMP `1,261 Target Price - 4QCY2012 Result Update Cement. Quarterly results (Standalone) Investment Period -

Aurobindo Pharma BUY. Performance Highlights CMP. `686 Target Price `877. 3QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Quick take. Ashok Leyland Ltd BUY. Scrappage policy to drive faster growth. Target Price. Investment Period 12 Months. 3-year price chart

Blue Star Ltd BUY. Performance Update. CMP Target Price `754 `867. 4QFY2018 Result Update Cons. Durable. 3-year price chart.

NIIT BUY. Performance Highlights CMP. `55 Target Price `68. 4QFY2011 Result Update Education. Investment Period 12 Months

TV Today Network BUY. Go with the market leader. CMP Target Price `297 `363. Initiating Coverage Media. 3-year price chart

Aurobindo Pharma BUY. Performance Highlights. `708 Target Price CMP `823. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 months

Cadila Healthcare ACCUMULATE. Performance Highlights. CMP 860 Target Price QFY2013 Result Update Pharmaceutical. Key financials (Consolidated)

Prakash Industries BUY. Performance Highlights. CMP Target Price `81 `124. 3QFY2011 Result Update Steel

United Phosphorus ACCUMULATE. Performance Highlights `754. CMP Target Price. 2QFY2018 Result Update Agrichemical. 3-year price chart

Transcription:

Jan-16 Jun-16 Nov-16 Apr-17 Sep-17 Feb-18 Jul-18 Dec-18 3QFY2019 Result Update IT January 11, 2019 Tata Consultancy Services (TCS) Performance highlights (` cr) 3QFY19 2QFY19 % chg (QoQ) 3QFY18 % chg (yoy) Net revenue 37,338 36,854 1.3 30,904 20.8 Adj. EBITDA 7,065 10,364 (31.8) 8,287 (14.7) Adj. EBITDA margin (%) 27.2 28.1 (92)bp 26.8 39bp Adj. PAT 8,105 7,901 2.6 6,531 24.1 TCS posted a 0.7% sequential growth in USD revenues to US$5,250mn v/s US$5,215mn in 2QFY2019. In rupee terms, revenues came in at `37,338cr V/s `36,854cr, up 1.3% QoQ. In Constant Currency (CC) terms, the company posted a 1.8% QoQ growth. On profitability front, EBIT margin showed a dip of ~90bps QoQ to 25.6%. Consequently, PAT came in at 8,105cr v/s `7,901cr in 2QFY2019, up of 2.6% QoQ. We recommend a neutral rating on the stock. Quarterly highlights: TCS posted a 0.7% sequential growth in USD revenues to US$5,250mn v/s US$5,215mn in 2QFY2019. In Constant Currency (CC) terms, the company posted a 1.8% QoQ growth. Geography wise, the growth was broadly well spread. In terms of verticals, key verticals BFSI, Retail & CPG & Communication & Media registered a yoy CC growth of 8.6%, 10.5% and 10.8% respectively. Other verticals like Manufacturing & Technology Services posted yoy growth of 6.7% and 5.8% on CC terms. On profitability front, EBIT margin showed a dip of ~90bps QoQ to 25.6%. Consequently, PAT came in at 8,105cr V/s `7,901cr in 2QFY2019, up 2.6% QoQ. Outlook and valuation: Over FY2018-21E, we expect TCS to post revenue CAGR of 9.5% & 13.1% in USD & INR terms respectively. The company highlighted that it stands comfortable in sustaining the EBIT margin in the range of 26-28%. On the EBIT and PAT fronts, we expect the company to post 13.4% and 11.7% CAGR over FY2018-21E respectively. The stock is trading at 21.3x FY2020E EPS of `88.7.Valuations already discount a robust medium growth & favorable operating environment and valuations are higher than its P/E averages. However, given the good cash yield we recommend a Neutral. Key financials (Consolidated, IFRS) Y/E March (` cr) FY2018 FY2019 FY2020E FY2021E Net sales 123,104 149,085 163,248 177,941 % chg 4.4 21.1 9.5 9.0 Net profit 25,826 31,194 33,284 36,030 % chg (1.8) 20.8 6.7 8.3 EBITDA margin (%) 26.6 27.2 26.7 26.7 EPS (`) 67.5 83.1 88.7 96.0 P/E (x) 28.0 22.7 21.3 19.7 P/BV (x) 8.2 8.4 7.5 6.7 RoE (%) 29.5 36.9 35.2 34.2 RoCE (%) 28.0 35.1 33.8 33.1 EV/Sales (x) 5.3 4.4 3.9 3.6 EV/EBITDA (x) 19.8 16.1 14.7 13.3 ; Note: CMP as of January 10, 2018 NEUTRAL CMP `1,889 Target Price Investment Period 12 Months Stock Info Sector IT Market Cap (` cr) 708,507 Net Debt (` cr) (45,288) Beta 0.3 52 Week High / Low 2,273/1,349 Avg. Daily Volume 192,405 Face Value (`) 1 BSE Sensex 36,107 Nifty 10,822 Reuters Code TCS.BO Bloomberg Code TCS@IN Shareholding Pattern (%) Promoters 72.1 MF / Banks / Indian Fls 7.8 FII / NRIs / OCBs 16.1 Indian Public / Others 4.1 Abs.(%) 3m 1yr 3yr Sensex 2.7 4.9 45.4 TCS (1.1) 34.5 59.8 3-Year Daily Price Chart 2,500 2,000 1,500 1,000 500 0 Sarabjit kour Nangra +91 22 3935 7800 Ext: 6806 sarabjit @angelbroking.com Please refer to important disclosures at the end of this report 1

Exhibit 1: 3QFY2019 performance (Consolidated, IFRS) (` cr) 3QFY2019 2QFY2019 % chg (QoQ) 3QFY2018 % chg (yoy) 9MFY2019 9MFY2018 % chg(yoy) Net revenue 37,338 36,854 1.3 30,904 20.8 1,08,453 91,029 19.1 Cost of revenue 21,142 20,607 2.6 17,356 21.8 61,434 51,255 19.9 Gross profit 16,196 16,247 (0.3) 13,548 19.5 47,019 39,774 18.2 SG&A expense 6,039 5,883 2.7 5,261 14.8 17,522 15,910 10.1 EBITDA 10,157 10,364 (2.0) 8,287 22.6 29,497 23,864 23.6 Dep. and Amortization 593 593-506 17.2 1,584 1,509 5.0 EBIT 9,564 9,771 (2.1) 7,781 22.9 27,913 22,355 24.9 Other income 1,147 593 93.4 864 32.8 2,948 2,608 13.0 PBT 10,711 10,364 3.3 8,645 23.9 30,861 24,963 23.6 Income tax 2,590 2,437 6.3 2,100 23.3 7,451 6,008 24.0 PAT 8,121 7,927 2.4 6,545 24.1 23,410 18,955 23.5 Earnings in affiliates - - - - - - - Minority interest 16 26 14 - - 33 Reported PAT 8,105 7,901 2.6 6,531 24.1 23,410 18,922 23.7 Adj. PAT 8,105 7,901 2.6 6,531 24.1 23,410 18,922 23.7 EPS 21.6 20.7 4.5 16.8 28.3 62.4 49.5 26.1 Gross margin (%) 43.4 44.1 (71)bps 43.8 (46)bps 43.4 43.7 (34)bps EBITDA margin (%) 27.2 28.1 (92)bps 26.8 39bps 27.2 26.2 98bps EBIT margin (%) 25.6 26.5 (90)bps 25.2 44bps 25.7 24.6 118bps Key geographies & verticals doing well TCS posted a 3.2% sequential growth in USD revenues to US$5,250mn v/s US$5,215mn in 2QFY2019. In Constant Currency (CC) terms, the company posted a 1.8% QoQ growth. Geography wise, the growth was broadly well spread. USA - North America & Latin America registered a yoy CC growth of 8.2% and 7.6% respectively. In Europe- UK & Continental Europe registered a yoy CC growth of 25.1% and 17.6% respectively. India & Asia Pacific registered a yoy CC growth of 9.7% and 12.6% respectively. In terms of verticals, BFSI, Retail & CPG & Communication & Media registered a yoy CC growth of 8.6%, 10.5% and 10.8% respectively. Other verticals like Manufacturing & Technology Services posted yoy growth of 6.7% and 5.8% on CC terms. Growth in Digital was 52.7% yoy in CC terms and it now constitutes to 30.1% of total revenue. Digital was around 22.1% of sales in 3QFY2018. TCS pipeline expanded across segments and geographies. Total TCV of deals in 3QFY2019 amounted to US$ 5.9bn. January 11, 2019 2

Exhibit 2: Revenue growth (Industry wise on CC basis) % to revenue % chg (yoy) BFSI 30.8 8.6 Manufacturing 7.2 6.7 Communication & Media 6.9 10.8 Life sciences and healthcare 7.6 15.7 Retail and CPG 16.5 10.5 Energy and utilities 4.7 18.1 Technology & Services 7.6 5.8 Regional Markets & Others 18.7 22.6 Exhibit 3: Revenue growth (Geography wise in INR terms) % of revenue % chg (yoy) U.S. 51.2 8.2 Latin America 2.0 7.6 U.K. 15.5 25.1 Continental Europe 14.1 17.6 India 5.7 9.7 Asia Pacific 9.4 12.6 MEA 2.1 (3.3) Attrition rate inches up In 3QFY2019, TCS witnessed a gross addition of 12,534 employees and net addition of 6,827 employees, taking its total employee base to 4,17,929. During the quarter, the attrition rate (last twelve-month [LTM] basis) for the company increased to 11.2% from 10.9% in 2QFY2019. Exhibit 4: Hiring & attrition trend Particulars 3QFY18 4QFY18 1QFY19 2QFY19 3QFY19 Net addition 3,404 1,667 4,118 5,877 6,827 Total employee base 3,90,880 3,94,998 4,00,875 4,11,102 4,17,929 Attrition (%) - LTM basis 11.9 11.8 11.7 10.9 11.2 Margin dips; mainly driven by subcontracting costs On the operating front, the company reported EBITDA and EBIT margins at 27.2% and 25.6%, i.e. a dip of 92ps and 90bps QoQ respectively. A major part of the dip was on back of subcontracting costs. Sub-con costs were 7.9% of revenues (the highest in recent history) compared to 7.2% in 2QFY2019. The company has maintained an EBIT margin target of 26-28%. January 11, 2019 3

(%) TCS 3QFY2019 Result Update Exhibit 5: Adj. Margin profile (%) 30 26.8 27.0 26.2 28.1 27.2 25 25.2 25.4 25.0 26.5 25.6 20 15 3QFY18 4QFY18 1QFY19 2QFY19 3QFY19 EBITDA margin EBIT margin Client metrics The client pyramid during the quarter witnessed a qualitative improvement with client additions seen in the higher revenue brackets. The clients in US$10mn+ revenue band increased by 7 and in US$100mn+ revenue band increased by 1. Exhibit 6: Client pyramid 3QFY18 4QFY18 1QFY19 2QFY19 3QFY19 US$1mn 5mn 456 468 470 476 477 US$5mn 10mn 148 145 153 148 149 US$10mn 20mn 134 143 149 152 159 US$20mn 50mn 109 110 109 115 112 US$50mn 100mn 57 59 57 54 54 US$100mn plus 37 38 40 44 45 Outlook & Valuations Over FY2018-21E, we expect TCS to post revenue CAGR of 9.5% & 13.1% in USD & INR terms respectively. The company highlighted that it stands comfortable in sustaining the EBIT margin in the range of 26-28%. On the EBIT and PAT fronts, we expect the company to post 13.4% and 11.7% CAGR over FY2018-21E respectively. The stock is trading at 21.3x FY2020E EPS of `88.7. Valuations already discount a robust medium growth and favorable operating environment and is at slight premium to its long-term P/E averages. However, given the cash yield we recommend a Neutral. January 11, 2019 4

Exhibit 7: Key assumptions FY2020E FY2021E Revenue growth (USD) 9.5 9.0 USD-INR rate (realized) 71.0 71.0 Revenue growth (%) 9.5 9.0 EBITDA margin (%) 26.7 26.7 Tax rate (%) 25.0 25.0 EPS growth (%) 6.7 8.3 Company background TCS is Asia's largest IT services provider and is amongst the top 10 technology firms in the world. The company has a global footprint with an employee base of over 4lakh professionals, offering services to more than 1,000 clients across various industry segments. The company has one of the widest portfolios of service offerings, spanning across the entire IT service value chain from traditional application development and maintenance to consulting and package implementation to products and platforms. January 11, 2019 5

Profit & Loss statement (Consolidated, IFRS) Y/E March (` cr) FY2017 FY2018 FY2019 FY2020E FY2021E Net sales 117,966 123,104 149,085 163,248 177,941 Cost of revenue 64,764 69,072 82,444 90,276 98,401 Gross profit 53,202 54,032 66,641 72,972 79,539 % of net sales 45.1 43.9 44.7 44.7 44.7 SGA expenses 20,755 21,314 26,090 29,385 32,029 % of net sales 17.6 17.3 17.5 18.0 18.0 EBITDA 32,447 32,718 40,551 43,587 47,510 % of net sales 27.5 26.6 27.2 26.7 26.7 Dep. and amortization 2123 2216 2534 2775 3025 % of net sales 1.8 1.8 1.7 1.7 1.7 EBIT 30,324 30,502 38,017 40,812 44,485 % of net sales 25.7 24.8 25.5 25.0 25.0 Other income, net 4189 3590 3700 3700 3700 Profit before tax 34,513 34,092 41,717 44,512 48,185 Provision for tax 8,156 8,212 10,429 11,128 12,046 % of PBT 23.6 24.1 25.0 25.0 25.0 PAT 26,357 25,880 31,288 33,384 36,139 Minority interest 68 54 94 100 108 Extra-ordinary (Exp.)/ Inc. Reported PAT 26,289 25,826 31,194 33,284 36,030 Adj. PAT 26,289 25,826 31,194 33,284 36,030 Diluted EPS (`) 68.7 67.5 83.1 88.7 96.0 January 11, 2019 6

Balance sheet (Consolidated, IFRS) Y/E March (` cr) FY2017 FY2018 FY2019 FY2020E FY2021E Assets Cash and cash equivalents 3,597.0 4,883.0 5,240.4 5,326.2 4,782.0 Other current financial assets - 6,395 6,395 6,395 6,395 Accounts receivable 22,684 24,943 27,437 30,181 33,199 Unbilled revenues 5,351 6,686 8,097 8,866 9,664 Other current assets 7,258 2,610 2,610 2,610 2,611 Property and equipment 11,741 11,600 11,700 11,800 11,900 Intangible assets and goodwill 3,768 3,896 3,896 3,896 3,896 Investments 41,980 36,008 30,908 39,747 50,074 Other non-current assets 8,974 12,034 12,034 12,034 12,034 Total assets 105,353 109,055 108,318 120,856 134,555 Liabilities Current liabilities 14,294 17,828 20,146 22,765 25,724 Short term borrowings 218 193 193 193 194 Redeemable preference shares - - - - - Long term debt 71 54 54 54 55 Other non-current liabilities 2,089 2,935 2,935 2,935 2,935 Minority interest 366 402 402 402 403 Shareholders funds 88,315 87,643 84,588 94,507 105,244 Total liabilities 105,353 109,055 108,318 120,856 134,555 January 11, 2019 7

Cash flow statement (Consolidated, IFRS) Y/E March (` cr) FY2017 FY2018 FY2019 FY2020E FY2021E Pre-tax profit from oper. 26,357 25,880 31,288 33,384 36,139 Depreciation 2,123 2,216 2,534 2,775 3,025 Exp. (deferred)/written off - - - - - Pretax cash from oper 28,480 28,096 33,822 36,159 39,164 Other inc./prior period ad 2,123 2,216 2,534 2,775 3,025 Net cash from operations 30,604 30,312 36,356 38,934 42,189 Tax 8,156 8,212 10,429 11,128 12,046 Cash profits 22,448 22,100 25,927 27,806 30,143 (Inc)/dec in acc. recv. 1,389 (2,259) (2,494) (2,744) (3,018) (Inc)/dec in unbilled rev. (1,359) (1,335) (1,411) (769) (798) (Inc)/dec in oth. current asst. (1,283) 4,648 - - (1) Inc/(dec) in current liab. 49 141 (100) (100) (100) Net trade working capital (1,204) 1,195 (4,005) (3,613) (3,917) Cash flow from opert. actv. 21,243 23,295 21,922 24,194 26,225 (Inc)/dec in fixed assets 49 141 (100) (100) (100) (Inc)/dec in investments (14,325) (423) 5,100 (8,839) (10,327) (Inc)/dec in intangible asst. (178) 128 - - - (Inc)/dec in non-cur.asst. 2,945 (3,060) - - - Cash flow from invt. actv. (11,509) (3,214) 5,000 (8,939) (10,427) Inc/(dec) in debt 44 (42) - - - Inc/(dec) in minority int. 12 36 - - - Dividends (19,993) (11,258) (18,248) (23,365) (25,293) Others 10,202 (8,816) (8,673) 8,111 9,494 Cash flow from finan. actv. (9,735) (20,080) (26,921) (15,254) (15,799) Cash generated/(utilized) 1,735 1,286 357 86 (544) Cash at start of the year 1,862 3,597 4,883 5,240 5,326 Cash at end of the year 3,597 4,883 5,240 5,326 4,782 January 11, 2019 8

Key ratios Y/E March FY2017 FY2018 FY2019 FY2020E FY2021E Valuation ratio(x) P/E (on FDEPS) 27.5 28.0 22.7 21.3 19.7 P/CEPS 25.4 25.8 21.0 19.7 18.1 P/BVPS 8.2 8.2 8.4 7.5 6.7 Dividend yield (%) 1.2 1.3 2.2 2.8 3.1 EV/Sales 5.5 5.3 4.4 3.9 3.6 EV/EBITDA 20.0 19.8 16.1 14.7 13.3 EV/Total assets 6.2 5.9 6.0 5.3 4.7 Per share data (`) EPS 68.7 67.5 83.1 88.7 96.0 Cash EPS 74.3 73.3 89.9 96.1 104.1 Dividend 23.5 25.0 41.6 53.2 57.6 Book value 231 229 225 252 280 DuPont analysis Tax retention ratio (PAT/PBT) 0.8 0.8 0.8 0.8 0.8 Cost of debt (PBT/EBIT) 1.1 1.1 1.1 1.1 1.1 EBIT margin (EBIT/Sales) 0.3 0.2 0.3 0.3 0.3 Asset turnover ratio (Sales/Assets) 1.1 1.1 1.4 1.4 1.3 Leverage ratio (Assets/Equity) 1.2 1.2 1.3 1.3 1.3 Operating ROE 29.8 29.5 37.0 35.3 34.3 Return ratios (%) RoCE (pre-tax) 28.8 28.0 35.1 33.8 33.1 Angel RoIC 50.7 49.4 57.8 58.8 60.7 RoE 29.8 29.5 36.9 35.2 34.2 Turnover ratios(x) Asset turnover (fixed assets) 10.0 10.6 12.7 13.8 15.0 Receivables days 70 74 67 67 68 January 11, 2019 9

Research Team Tel: 022-39357800 E-mail: research@angelbroking.com Website: www.angelbroking.com DISCLAIMER Angel Broking Limited (hereinafter referred to as Angel ) is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, Metropolitan Stock Exchange Limited, Multi Commodity Exchange of India Ltd and National Commodity & Derivatives Exchange Ltd It is also registered as a Depository Participant with CDSL and Portfolio Manager and Investment Adviser with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market. Angel or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the contrary view, if any The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Disclosure of Interest Statement TCS 1. Financial interest of research analyst or Angel or his Associate or his relative No 2. Ownership of 1% or more of the stock by research analyst or Angel or associates or No relatives 3. Served as an officer, director or employee of the company covered under Research No 4. Broking relationship with company covered under Research No Ratings (Based on expected returns Buy (> 15%) Accumulate (5% to 15%) Neutral (-5 to 5%) over 12 months investment period): Reduce (-5% to -15%) Sell (< -15) January 11, 2019 10